Gastric dumping syndrome medical therapy
Gastric dumping syndrome Microchapters |
Differentiating Gastric dumping syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Gastric dumping syndrome medical therapy On the Web |
American Roentgen Ray Society Images of Gastric dumping syndrome medical therapy |
Risk calculators and risk factors for Gastric dumping syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Mainstay therapy for the management of dumping syndrome includes diet and pharmacological intervention.
Medical Therapy
Medical therapy for dumping syndrome includes diet and drug therapy.
Level of evidence | Type of evidence |
---|---|
I | Evidence from meta-analysis of multiple, well-designed, controlled studies (randomized trials with low false-positive and low false-negative errors) |
II | Evidence from at least 1 well-designed, quasi-experimental study (randomized trials with high false-positive and high false-negative errors) |
III | Evidence from well-designed, quasi-experimental studies (nonrandomized, controlled, single-group, pre–post, cohort and time or matched case–control series) |
IV | Evidence from well-designed, non-experimental studies (comparative and correlational descriptive and case studies) |
V | Evidence from case reports |
Grade of recommendation | Level of evidence |
A | Level I evidence or consistent findings from multiple studies (level II, III or IV) |
B | Level II, III or IV evidence with generally consistent findings |
C | Level II, III or IV evidence with inconsistent findings |
D | Little or no systematic empirical evidence |
Diet
Dietary Modifications (Level III; Grade B)
- Decrease carbohydrate intake
- Avoid simple sugars like soda, candy sweets, and cookies
- Increase protein intake
- Increase fat intake
- Increase fiber intake
- Fluid restriction
- Dairy and dairy product restriction
- Shorter meals
- Lying supine for 30 minutes after a meal
Dietary Foods
The following is a table that illustrates the types of food to take and avoid in the case of dumping syndrome.
Breads, Cereals, Rice and Pasta | Foods To Choose | Foods to Avoid |
---|---|---|
|
|
|
Fruits | Foods to Choose | Foods To Avoid |
|
|
|
Milk and Dairy Products | Foods To Choose | Foods to Avoid |
|
|
|
Meats, Poultry, Fish, Dry Beans, Peas, Eggs and Cheese | Foods to Choose | Foods to Avoid |
|
|
|
Vegetables | Foods to Choose | Foods to Avoid |
|
|
|
Fats, Condiments and Beverages | Foods to Choose | Foods to Avoid |
|
| |
Snacks, Sweets, and Desserts | Foods to Choose | Foods to Avoid |
|
|
Dietary Supplements (Level III; Grade C)
- Delay glucose absorption:
- Pectin
- Guar gum
- Glucomannan
Drug Therapy
The two main stays for pharmacological intervention are Acarbose (Glucobay, Precose, Prandase) and Somatostatin analogues such as Octreotide (Sandostatin).
Acarbose (Level III; Grade B) | Octreotide (Level II; Grade A) | |
---|---|---|
Use | Late dumping syndrome | Early and Late dumping syndrome |
Mechanism of Action | Inhibits carbohydrate absorption | Strong inhibitor of the gut hormones (especially insulin) |
Dose |
|
|
Effect |
|
|
Additional information |
|
|
Somatostatin analogues
- Pasireotide has a higher affinity than Octreotide and is more effective but it does not reduce dumping syndrome symptoms as well as Octreotide.
- Even though it has been safe and effective no results of its clinical trials have been published to date.
Drug | Dose | Effect |
---|---|---|
Tolbutamide[1] | 0.25-0.75 g, TID | Subjective improvement |
Propranolol[2] | 10 mg, QID | Reduced early dumping |
Cyproheptadine[3] | 4-8 mg, TID | Preventing vasomotor symptoms |
Methysergide maleate[4] | 4-8 mg, TID | Reduced vasomotor symptoms |
Verapamil[5] | 120-240 mg, QD | Reduced vasomotor symptoms |
Acarbose[6] | 50-100 mg, TID | Reduced late dumping |
Octreotide[7] | 25-100 mcg, TID | Reduced vasomotor symptoms |
Pantoprazole (PPI)[8] | Subjective improvement | |
Cholestyramine[9] | Subjective improvement | |
Diazoxide[10] | 75-260 mg, QD | Subjective improvement |
Nifedipine[11] | 30 mg, QD | Reduced hypoglycemic symptoms |
Exendin 9-39[12] | 7500 pmol/kg prime | Reduced hypoglycemic symptoms |
- After RYGB surgery, bioavailability is decreased in drugs such as (eg, amoxicillin, azithromycin, cyclosporine A, levothyroxine, nitrofurantoin, mycophenolic acid, phenytoin, phenobarbital sirolimus, tacrolimus, tamoxifen). Surgeries that decrease the stomach size may increase toxicity of nonsteroidal anti-inflammatory drugs, salicylates, oral bisphosphonates, and oral iron tablet formulations. Any procedure that causes dumping; increases gut transit time and may decease drug absorption.
- ↑ Sigstad H (1969). "Effect of tolbutamide on the dumping syndrome". Scand. J. Gastroenterol. 4 (3): 227–31. PMID 5346670.
- ↑ Niv Y (1988). "The early dumping syndrome and propranolol". Ann. Intern. Med. 108 (6): 910–1. PMID 3369789.
- ↑ Leichter SB, Permutt MA (1975). "Effect of adrenergic agents on postgastrectomy hypoglycemia". Diabetes. 24 (11): 1005–10. PMID 1183731.
- ↑ Bernard PF, Baschet C, Le Henand F, Bouderlique JR, Lortat-Jacob JL (1970). "[Treatment of 65 cases of dumping syndrome with methysergide in recently gastrectomized patients]". Presse Med (in French). 78 (12): 549–50. PMID 5439191.
- ↑ Tabibian N (1990). "Successful treatment of refractory post-vagotomy syndrome with verapamil (Calan SR)". Am. J. Gastroenterol. 85 (3): 328–9. PMID 2309689.
- ↑ Hasegawa T, Yoneda M, Nakamura K, Ohnishi K, Harada H, Kyouda T, Yoshida Y, Makino I (1998). "Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome". J. Gastroenterol. Hepatol. 13 (12): 1201–6. PMID 9918426.
- ↑ Vecht J, Masclee AA, Lamers CB (1997). "The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment". Scand. J. Gastroenterol. Suppl. 223: 21–7. PMID 9200302.
- ↑ Sanaka M, Yamamoto T, Kuyama Y (2010). "Effects of proton pump inhibitors on gastric emptying: a systematic review". Dig. Dis. Sci. 55 (9): 2431–40. doi:10.1007/s10620-009-1076-x. PMID 20012198.
- ↑ Barkun AN, Love J, Gould M, Pluta H, Steinhart H (2013). "Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment". Can. J. Gastroenterol. 27 (11): 653–9. PMC 3816948. PMID 24199211.
- ↑ Vilarrasa N, Goday A, Rubio MA, Caixàs A, Pellitero S, Ciudin A, Calañas A, Botella JI, Bretón I, Morales MJ, Díaz-Fernández MJ, García-Luna PP, Lecube A (2016). "Hyperinsulinemic Hypoglycemia after Bariatric Surgery: Diagnosis and Management Experience from a Spanish Multicenter Registry". Obes Facts. 9 (1): 41–51. doi:10.1159/000442764. PMC 5644871. PMID 26901345.
- ↑ Guseva N, Phillips D, Mordes JP (2010). "Successful treatment of persistent hyperinsulinemic hypoglycemia with nifedipine in an adult patient". Endocr Pract. 16 (1): 107–11. doi:10.4158/EP09110.CRR. PMC 3979460. PMID 19625246.
- ↑ Salehi M, Gastaldelli A, D'Alessio DA (2014). "Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass". Gastroenterology. 146 (3): 669–680.e2. doi:10.1053/j.gastro.2013.11.044. PMC 3943944. PMID 24315990.